The PI3K/AKT/mTOR and CDK4/6 Pathways in Endocrine Resistant HR+/HER2− Metastatic Breast Cancer: Biological Mechanisms and New Treatments

Endocrine-based treatments are the normal standard-of-care in women with hormone receptor-positive/Human Epidermal growth factor Receptor 2-negative metastatic breast cancer. Despite the well-known efficacy of these drugs as first-line therapies, about 50% of women develop endocrine resistance and d...

Descripción completa

Detalles Bibliográficos
Autores principales: Presti, Daniele, Quaquarini, Erica
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6770492/
https://www.ncbi.nlm.nih.gov/pubmed/31450618
http://dx.doi.org/10.3390/cancers11091242

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6770492/
https://www.ncbi.nlm.nih.gov/pubmed/31450618
http://dx.doi.org/10.3390/cancers11091242

Ejemplares similares